Niagen Bioscience (NAGE) Revenue (2010 - 2026)

Niagen Bioscience (NAGE) has reported Revenue for 17 consecutive years, with $31.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Revenue rose 3.26% year-over-year to $31.5 million; the TTM figure through Mar 2026 stood at $130.4 million (up 20.84% YoY), while the FY2025 annual figure was $129.4 million, up 29.95% from the prior year.
• Revenue slipped to $31.5 million in Q1 2026 per NAGE's latest filing, from $33.8 million in the prior quarter.
• Across five years, Revenue topped out at $34.0 million in Q3 2025 and bottomed at $16.7 million in Q2 2022.
• Historically, Revenue has averaged $24.5 million across 5 years, with a median of $22.6 million in 2023.
• Annual changes were most pronounced in 2022 — Revenue slipped 5.46% — and 2025, when it soared 37.59%.
• Niagen Bioscience's Revenue stood at $21.0 million in 2022, then climbed by 0.95% to $21.2 million in 2023, then surged by 37.41% to $29.1 million in 2024, then advanced by 16.19% to $33.8 million in 2025, then decreased by 6.99% to $31.5 million in 2026.
• Business Quant data shows NAGE's Revenue at $31.5 million in Q1 2026, $33.8 million in Q4 2025, and $34.0 million in Q3 2025.